Clinical and Pharmacokinetic Characteristics of Intracavitary Administration of Pegylated Liposomal Encapsulated Doxorubicin in Dogs with Splenic Hemangiosarcoma

Sørenmo, Karin U.; Samluk, Marissa; Clifford, Craig; Baez, Jennifer; Barrett, Jeffrey S.; Poppenga, Robert H.; Overley, Beth; Skorupski, Katherine A; Oberthaler, Karen; Winkle, Thomas Van; Seiler, Gabriela; Shofer, Frances S.

doi:10.1892/06-214.1

Cited by 20 publications

(21 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although we did not reach the 36 dogs, the deficit of two dogs would not have made a significant difference to outcome. The median survival times of 166 and 172 days for PL‐DOX and free doxorubicin, respectively, is not significantly different from the 131–145 days reported in literature 8,11,12,27 . The 1‐year survival rate of the combined group was 22.1%.…”

Section: Discussionmentioning

confidence: 50%

“…In the study of Sorenmo et al , 27 in which PL‐DOX was given intraperitoneally, a change in the pattern of metastasis was noticed, with fewer omental and serosal metastases than seen in a historical control group. It was suggested that PL‐DOX might have a better tumour penetration on the surface or implant metastases because of the intraperitoneal routing.…”

Section: Discussionmentioning

confidence: 95%

“…The 1‐year survival rate of the combined group was 22.1%. In a recent publication, adjuvant intraperitoneal administration of PL‐DOX in 14 dogs with splenic HSA also did not improve outcome (median survival 131 days) 27 …”

Section: Discussionmentioning

confidence: 96%

See 2 more Smart Citations

A randomized controlled study into the efficacy and toxicity of pegylated liposome encapsulated doxorubicin as an adjuvant therapy in dogs with splenic haemangiosarcoma

Teske

Rutteman

Kirpenstein

et al. 2011

Vet Comparative Oncology

View full text Add to dashboard Cite

Safety and efficacy of pegylated liposome encapsulated doxorubicin (PL-DOX) was compared with free doxorubicin as an adjuvant monotherapy in dogs with splenic haemangiosarcoma after splenectomy in a randomized prospective clinical trial. A total of 17 dogs in each group were treated. No significant difference in survival between the two treatments was found. The calculated median overall survival time for the 34 dogs was 166 days [95% confidence interval (CI) 148-184]. The ½ year and one-year survival was 41.2% (95% CI 24.8-56.9) and 22.7% (95% CI 9.9-37.4), respectively. In dogs treated with PL-DOX, a desquamating dermatitis like palmar-plantar erythrodysesthesia (PPES) was seen in two dogs, while three other dogs showed anaphylactic reactions. Cardiotoxicity was not seen in either treatment groups.

show abstract

Section: Discussionmentioning

confidence: 50%

Section: Discussionmentioning

confidence: 95%

See 1 more Smart Citation

A randomized controlled study into the efficacy and toxicity of pegylated liposome encapsulated doxorubicin as an adjuvant therapy in dogs with splenic haemangiosarcoma

Teske

Rutteman

Kirpenstein

et al. 2011

Vet Comparative Oncology

View full text Add to dashboard Cite

show abstract

“…Doxorubicin and its analog epirubicin have been used: as single agents in the standard 3 wk protocol; in a dose-intense fashion (2 wk protocol); in combination with cyclophosphamide; or with cyclophosphamide and vincristine. [20][21][22][23][24][25][26] There have been no studies specifically evaluating the treatment of dogs with grossly metastatic HSA, a common presentation in the cases of HSA. 8,10,12 Nonresectable, primary, noncutaneous HSA appears to carry a negative prognosis for overall survival (OS), yet the use of chemotherapy or palliative radiation therapy has been largely unexplored.…”

Section: Introductionmentioning

confidence: 99%

Treatment with DAV for Advanced-Stage Hemangiosarcoma in Dogs

Dervisis

Domı́nguez

Newman

et al. 2011

Journal of the American Animal Hospital Association

View full text Add to dashboard Cite

Hemangiosarcoma (HSA) is an aggressive disease that is fairly common in the dog. The authors evaluated a doxorubicin, dacarbazine, and vincristine (DAV) combination protocol in dogs with nonresectable stage II and stage III HSA. Twenty-four dogs were enrolled in this prospective, phase 2 study. Doxorubicin and dacarbazine were administered on day 1 while vincristine was administered on days 8 and 15. The protocol was repeated every 21 days for a maximum of six cycles or until disease progression. Toxicity and efficacy were assessed by clinical and laboratory evaluation and by questionnaires completed by the owners. Of the 24 included dogs, 19 were evaluable for response. The response rate (including five complete responses and four partial responses) was 47.4%. Median time to tumor progression was 101 days and median overall survival was 125 days.Significant toxicities were noted, including 41 high-grade hematologic and 12 high-grade gastrointestinal toxic events.

show abstract

“…Most chemotherapeutic protocols used for lymphoma incorporate the anthracycline agent doxorubicin. Cardiotoxicity after doxorubicin administration has been reported in humans, dogs and cats . It has been reported that doxorubicin administration can lead to a cardiotoxic effect in humans, dogs and cats .…”

Section: Introductionmentioning

confidence: 99%

Assessment of cardiac troponin I (cTnI) and tissue velocity imaging (TVI) in 14 dogs with malignant lymphoma undergoing chemotherapy treatment with doxorubicin

Tater

Eberle

Hungerbuehler

et al. 2015

Vet Comparative Oncology

View full text Add to dashboard Cite

Doxorubicin has been shown to be cardiotoxic at high doses but is an efficacious chemotherapeutic agent in the treatment of canine lymphoma. Echocardiographic measurements and serum ultrasensitive cardiac troponin I (cTnI) levels were obtained before and after doxorubicin administration in 14 dogs diagnosed with lymphoma. The aim of this prospective study was to evaluate changes in cTnI concentrations and tissue velocity imaging (TVI) values in dogs with lymphoma undergoing chemotherapy with doxorubicin. A total of 182 cTnI and 1017 TVI measurements were performed. Standard echocardiographic parameters, tissue Doppler indices and cTnI concentrations did not differ at any time point within a 12-week cyclic combination protocol. In conclusion, the use of doxorubicin at standard doses in the treatment of canine lymphoma may not be associated with significant myocardial damage.

show abstract

Clinical and Pharmacokinetic Characteristics of Intracavitary Administration of Pegylated Liposomal Encapsulated Doxorubicin in Dogs with Splenic Hemangiosarcoma

Cited by 20 publications

References 23 publications

A randomized controlled study into the efficacy and toxicity of pegylated liposome encapsulated doxorubicin as an adjuvant therapy in dogs with splenic haemangiosarcoma

A randomized controlled study into the efficacy and toxicity of pegylated liposome encapsulated doxorubicin as an adjuvant therapy in dogs with splenic haemangiosarcoma

Treatment with DAV for Advanced-Stage Hemangiosarcoma in Dogs

Assessment of cardiac troponin I (cTnI) and tissue velocity imaging (TVI) in 14 dogs with malignant lymphoma undergoing chemotherapy treatment with doxorubicin

Contact Info

Product

Resources

About